David Immanuel Thickman, MD | |
109 Sopris Mesa Dr, Carbondale, CO 81623-3150 | |
(952) 595-1100 | |
(612) 294-4903 |
Full Name | David Immanuel Thickman |
---|---|
Gender | Male |
Speciality | Radiology - Diagnostic Radiology |
Location | 109 Sopris Mesa Dr, Carbondale, Colorado |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1689650939 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2085R0202X | Radiology - Diagnostic Radiology | DR28103 (Colorado) | Primary |
Mailing Address | Practice Location Address |
---|---|
David Immanuel Thickman, MD 11995 Singletree Lane, Ste 500, Eden Prairie, MN 55344-5349 Ph: (952) 595-1301 | David Immanuel Thickman, MD 109 Sopris Mesa Dr, Carbondale, CO 81623-3150 Ph: (952) 595-1100 |
News Archive
Bio Light Israeli Life Sciences Investments Ltd., an emerging global ophthalmic company focused on the discovery, development and commercialization of products and product candidates which address ophthalmic conditions, announced today that its IOPtiMate system for the treatment of glaucoma has been approved by the Canadian Medical Devices Bureau, allowing the Company to commercialize the surgical system in Canada.
Ultramarathon runners can expect an approximate five-to-seven-day subjective recovery post race, according to research presented this week at the Association of Academic Physiatrists Annual Meeting in Sacramento, Calif. The study also looked at factors that affect physical recovery and a runner's ability to return to full running speed after participation in an ultramarathon.
Research completed at Johns Hopkins and the Greater Baltimore Medical Center has demonstrated that vaginal childbirth substantially increases the probability a woman will develop a pelvic floor disorder later in life.
In a rigorous new review of the antiarrhythmic drug dronedarone (Multaq), researchers at the Cedars-Sinai Heart Institute conclude that the controversial drug is only modestly effective and has no clear safety benefits.
› Verified 7 days ago